Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more
Level Biotechnology (3118) - Total Liabilities
Latest total liabilities as of September 2025: NT$237.03 Million TWD
Based on the latest financial reports, Level Biotechnology (3118) has total liabilities worth NT$237.03 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Level Biotechnology - Total Liabilities Trend (2017–2024)
This chart illustrates how Level Biotechnology's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Level Biotechnology Competitors by Total Liabilities
The table below lists competitors of Level Biotechnology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Defence Therapeutics Inc
OTCQB:DTCFF
|
USA | $4.18 Million |
|
brooqLy Inc.
PINK:BRQL
|
USA | $288.23K |
|
Paragon Union Bhd
KLSE:9407
|
Malaysia | RM82.48 Million |
|
Lakeside Holding Limited Common Stock
NASDAQ:LSH
|
USA | $12.12 Million |
|
Oba Makarnacılık San As
IS:OBAMS
|
Turkey | TL2.35 Billion |
|
Celularity Inc
NASDAQ:CELU
|
USA | $134.33 Million |
|
Polarx Ltd
AU:PXX
|
Australia | AU$3.20 Million |
|
VRX Silica Ltd
AU:VRX
|
Australia | AU$698.85K |
Liability Composition Analysis (2017–2024)
This chart breaks down Level Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Level Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Level Biotechnology (2017–2024)
The table below shows the annual total liabilities of Level Biotechnology from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$267.19 Million | -2.20% |
| 2023-12-31 | NT$273.20 Million | +1.14% |
| 2022-12-31 | NT$270.13 Million | +11.27% |
| 2021-12-31 | NT$242.78 Million | -0.32% |
| 2020-12-31 | NT$243.56 Million | +3.01% |
| 2019-12-31 | NT$236.43 Million | +30.19% |
| 2018-12-31 | NT$181.60 Million | -13.53% |
| 2017-12-31 | NT$210.03 Million | -- |